Genzyme reports positive top-line results of TOWER, a pivotal phase III trial for AUBAGIO(TM*) (teriflunomide) in relapsing multiple sclerosis Genzyme, 1 Jun 2012 Accessed on 4 Jun 2012 from http://www.businesswire.com/news/genzyme/20120531006926/en. CommentRecommendBookmarkWatch